Cutaneous Squamous cell Carcinoma- Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025

November 2017 | 131 pages | ID: CEE694FA5B6EN
DelveInsight

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight’s ‘Cutaneous Squamous Cell Carcinoma (cSCC) - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025’ report provides provides the comprehensive insights on the competitive landscape and market of Cutaneous Squamous Cell Carcinoma (cSCC).

The report covers the overview of the Cutaneous Squamous Cell Carcinoma along with the epidemiology and the market scenario in the 7MM – United States, EU5 (Germany, France, Spain Italy, United Kingdom) and Japan. The Report provides a comprehensive review of the unmet medical needs of the disease, market trends, drivers and market barriers.

The competitive landscape of the report covers both pipeline and marketed portfolio of the indication. Cutaneous Squamous Cell Carcinoma pipeline provides information on the therapeutic drugs in development and comparative analysis at various stages covering clinical and pre-clinical & discovery stages, therapeutics assessment by Monotherapy/Combination products and Molecule Type drug analysis. It also provides in-depth analysis on the Phase III profile covering clinical trial studies, recent developments and SWOT Analysis.

The Report includes detailed historical and forecasted epidemiology of Cutaneous Squamous Cell Carcinoma (cSCC) in the 7MM (till 2025). According to DelveInsight, the incident cases of Cutaneous Squamous Cell Carcinoma are expected to reach up to 871,530 by the end of 2025 at a CAGR of XX% for the forecast period i.e., 2015-2025. High incident cases were observed in United States as compared to EU5 and Japan.

The Report also covers the therapeutics market revenue, treatment practice/algorithm and detailed market size forecast of Cutaneous Squamous Cell Carcinoma from 2017 to 2025 segmented by seven major markets. United States contributes the major share of Cutaneous Squamous Cell Carcinoma market as compared to EU5 countries and Japan.

Market is driven by the use of chemotherapy such as Cisplatin, 5-Fluorouracil (5-FU), and Bleomycin, antibodies such as Cetuximab for the treatment of Cutaneous Squamous Cell Carcinoma.

The therapeutic market of Cutaneous Squamous Cell Carcinoma in 7MM is expected to reach USD XXX Million in 2025 at the CAGR of 5.5% for the forecast period i.e., 2015-2025.

KEY COVERAGE AND BENEFITS:

• Overview of the Global pipeline scenario for Cutaneous Squamous Cell Carcinoma, products and associated companies information
• Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities
• The report will help in developing business strategies by understanding the trends shaping and driving the global Cutaneous Squamous Cell Carcinoma (cSCC) market.
• Organize sales and marketing efforts by identifying the best opportunities for Cutaneous Squamous Cell Carcinoma (cSCC) in US, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
• The report provides historical as well as forecasted epidemiology of Cutaneous Squamous Cell Carcinoma (cSCC) in the 7MM covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025.
• To understand the future market competition in the global Cutaneous Squamous Cell Carcinoma (cSCC) market and Insightful review of the key market drivers and barriers.
• To understand the regulatory scenario in major markets.
• The Report also covers the detailed global historical and forecasted Cutaneous Squamous Cell Carcinoma (cSCC) market covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan from 2015-2025.

Contents

Report Introduction
Table of Contents
Market Overview at a Glance
Total Market Share Distribution of Cutaneous Squamous Cell Carcinoma for 7MM in 2016
Total Market Share Distribution of Cutaneous Squamous Cell Carcinoma for 7MM in 2025
Introduction
Signs and Symptoms
Pathophysiology
Sub-types of cSCC
Risk Factors
Staging of cSCC
Diagnosis
Epidemiology and Patient Population
Total number of Incident cases – Region Wise – (2016 & 2025)
Total number of Incident cases – 7MM Countries – (2016 & 2025)
United States
Germany
France
United Kingdom
Spain
Italy
Japan
Treatment Algorithm
United States
NCCN Guidelines
Europe
British Association of dermatology (BAD) Guidelines
French Dermatology Recommendations Association (aRED)
European Dermatology Forum
London Cancer Skin Pathway Board
National Cancer Institute
Unmet Needs
Marketed Drugs
5-Fluorouracil (5-FU)
MOA
Study
Xeloda
MOA
Study
Cisplatin
MOA
Study
Bleomycin
MOA
Study
Doxorubicin
MOA
Cetuximab
MOA
Study
Gefitinib
MOA
Study
Cutaneous Squamous Cell Carcinoma (cSCC): Country-Wise Market Analysis
7 Major Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) (2015-2025)
Region-Specific Market Distribution and Comparison
Overview on Cutaneous Squamous Cell Carcinoma (cSCC) (2016)
Overview on Cutaneous Squamous Cell Carcinoma (cSCC) (2025)
Global Cutaneous Squamous Cell Carcinoma (cSCC): Market Analysis
United States Market Size
Europe Market Outlook
Germany Market Size
France Market Size
United Kingdom Market Size
Spain Market Size
Italy Market Size
Japan Market Size
Market Drivers
Market Barriers
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight

List Of Tables

LIST OF TABLES

Table 1: Staging of Cutaneous Squamous Cell Carcinoma, 2017
Table 2: Total number of Incident cases - Region wise
Table 3: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in United States (2015-2025)
Table 4: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in Germany (2015-2025)
Table 5: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in France (2015-2025)
Table 6: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in United Kingdom (2015-2025)
Table 7: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in Spain (2015-2025)
Table 8: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in Italy (2015-2025)
Table 9: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in Japan (2015-2025)
Table 10: 7 MM Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Table 11: Region specific market distribution and comparison
Table 12: Cutaneous Squamous Cell Carcinoma (cSCC), Market Revenue (2016) as per the 7MM
Table 13: Cutaneous Squamous Cell Carcinoma(cSCC), Market Revenue (2025) as per the 7MM
Table 14: United States Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Table 15: Germany Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Table 16: France Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Table 17: United Kingdom Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Table 18: Spain Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Table 19: Italy Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Table 20: Japan Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)

List Of Figures

LIST OF FIGURES

Figure 1: Pathophysiology of Cutaneous Squamous Cell Carcinoma
Figure 2: Risk Factors of Squamous Cell Skin Carcinoma
Figure 3: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in United States (2015-2025)
Figure 4: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in Germany (2015-2025)
Figure 5: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in France (2015-2025)
Figure 6: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in United Kingdom (2015-2025)
Figure 7: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in Spain (2015-2025)
Figure 8: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in Italy (2015-2025)
Figure 9: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in Japan (2015-2025)
Figure 10: Clinical Presentation of Squamous Cell Skin Carcinoma
Figure 11: Primary and Adjuvant therapy for low risk Squamous Cell Carcinoma
Figure 12: Primary and Adjuvant therapy for High risk Squamous Cell Carcinoma
Figure 13: Treatment of Primary Cutaneous Squamous Cell Carcinoma
Figure 14: Treatment of Primary Cutaneous Squamous Cell Carcinoma
Figure 15: Region specific market distribution and comparison
Figure 16: Total 7 Major Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD, Million (2016)
Figure 17: Total 7 Major Market Size of Cutaneous Squamous Cell Carcinoma(cSCC) in USD, Million (2025)
Figure 18: United States Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Figure 19: Germany Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Figure 20: France Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Figure 21: United Kingdom Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Figure 22: Spain Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Figure 23: Italy Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Figure 24: Japan Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)